Tigilanol Tiglate

Preferred Label : Tigilanol Tiglate;

NCIt definition : A short-chain diterpene ester isolated from the seed of Fontainea picrosperma, with potential antineoplastic activity. Upon intratumoral administration, tigilanol tiglate disrupts mitochondrial functioning and induces mitochondrial swelling, which leads to oncolysis of tumor cells that are in direct contact of the agent. In addition, tigilanol tiglate activates protein kinase C (PKC) signaling cascade, which leads to an acute inflammatory response. This results in hypoxia and activates innate immune cells including neutrophils and macrophages, thereby further killing tumor cells. The activation of the beta-II isoform of PKC (PKC beta II ) also increases tumor vasculature permeability, which leads to the destruction of tumor vasculature.;

UNII : R1ZJT87990;

InChIKey : YLQZMOUMDYVSQR-FOWZUWBHSA-N;

CAS number : 943001-56-7;

Molecule name : EBC-46; EBI-46;

NCI Metathesaurus CUI : CL553826;

Details

Origin ID

C152622;

UMLS CUI

C4726858;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Protein Kinase C [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients